CreativeOne Wealth LLC Trims Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

CreativeOne Wealth LLC reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 22.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,779 shares of the biopharmaceutical company’s stock after selling 3,937 shares during the quarter. CreativeOne Wealth LLC’s holdings in Gilead Sciences were worth $1,116,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Tompkins Financial Corp increased its position in Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares during the period. Private Wealth Management Group LLC bought a new position in Gilead Sciences in the fourth quarter worth about $29,000. Fortitude Family Office LLC bought a new position in Gilead Sciences in the fourth quarter worth about $29,000. Sachetta LLC bought a new stake in Gilead Sciences during the 4th quarter valued at approximately $30,000. Finally, Rakuten Securities Inc. purchased a new position in shares of Gilead Sciences during the 4th quarter worth approximately $33,000. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

GILD has been the topic of several research reports. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and dropped their price target for the company from $91.00 to $82.00 in a research report on Thursday, February 22nd. Cantor Fitzgerald decreased their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research note on Wednesday, February 7th. Wells Fargo & Company cut their price objective on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a report on Monday, March 4th. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Finally, TD Cowen cut their price target on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Hold” and a consensus target price of $83.69.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.29% of the stock is owned by company insiders.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock traded up $0.38 during trading hours on Wednesday, reaching $67.67. 583,266 shares of the stock traded hands, compared to its average volume of 7,210,575. Gilead Sciences, Inc. has a one year low of $64.33 and a one year high of $87.86. The firm has a market capitalization of $84.31 billion, a price-to-earnings ratio of 186.92, a P/E/G ratio of 1.37 and a beta of 0.22. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. The company has a 50 day moving average price of $68.93 and a 200 day moving average price of $74.75.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. During the same quarter last year, the company posted $1.37 EPS. The company’s revenue was up 5.3% compared to the same quarter last year. On average, equities research analysts expect that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.55%. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.